Brief: Vyne Therapeutics Announces Selection Of Development Candidate Vyn202, A Potential Best-In-Class Oral Small Molecule Bd2-Selective Bet Inhibitor For Treatment Of Immuno-Inflammatory Conditions

YARROW BIOSCIENCE

01/05/2023 13:14

May 1 (Reuters) - Vyne Therapeutics Inc  VYNE.O :
    * VYNE THERAPEUTICS ANNOUNCES SELECTION OF DEVELOPMENT
CANDIDATE
VYN202, A POTENTIAL BEST-IN-CLASS ORAL SMALL MOLECULE
BD2-SELECTIVE BET INHIBITOR FOR THE TREATMENT OF
IMMUNO-INFLAMMATORY CONDITIONS
    * VYNE THERAPEUTICS INC - VYNE HAS INITIATED IND-ENABLING
STUDIES
FOR VYN202 AND INTENDS TO SUBMIT AN IND BY YEAR-END

Source text for Eikon:  ID:nGNX1QkWYr 
Further company coverage:  VYNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))